FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387116214> ?p ?o ?g. }

• W4387116214 abstract "Evidence suggests that chronic venous disease (CVD) may be a cardiovascular disorder, as patients with CVD are prone to developing arterial (atherosclerosis) and venous (thromboembolism) diseases. This may be partly explained by shared risk factors. Thus, patients with CVD or cardiovascular disease require careful history-taking and physical assessment to identify coexisting pathologies and risk factors. This article summarises a symposium at the XIX World Congress of the International Union of Phlebology held in Istanbul, Turkey, in September 2022. Common pathophysiological features of CVD and cardiovascular disease are endothelial injury, hypercoagulability and systemic inflammation. In CVD, inflammation primarily affects the microcirculation, with changes in capillary permeability, vein wall and valve remodelling and increase in oxidative stress. Once patients develop symptoms/signs of CVD, they tend to reduce their physical activity, which may contribute to increased risk of cardiovascular disease. Data show that the presence of CVD is associated with an increased risk of cardiovascular disease, including peripheral arterial disease and heart failure (HF), and the risk of adverse cardiovascular events increases with CVD severity. In addition, patients with cardiovascular disease, particularly those with HF, are at increased risk of venous thromboembolism (VTE) and should be assessed for VTE risk if they are hospitalised with cardiovascular disease. Therefore, CVD management must include a multi-specialty approach to assess risk factors associated with both the venous and arterial systems. Ideally, treatment should focus on the resolution of endothelial inflammation to control both CVD and cardiovascular disease. International guidelines recommend various conservative treatments, including venoactive drugs (VADs), to improve the symptoms/signs of CVD. Micronized purified flavonoid fraction (MPFF) is a VAD, with high-quality evidence supporting its use in relieving symptoms/signs of CVD and improving quality of life. Moreover, in large-scale observational studies, MPFF has shown superior effectiveness in real-world populations compared with other VADs. Video Abstract. (MP4 97173 kb).Blood vessel disease can affect both arteries and veins; when it affects arteries, it is called cardiovascular disease, and when it affects veins, it is called chronic venous disease (CVD). In most cases, the underlying disease process is similar, irrespective of the type of blood vessels affected, and the risk of both CVD and cardiovascular disease is increased by age, smoking, overweight/obesity and diabetes. If cardiovascular disease affects arteries in the legs, the symptoms can be similar to that of CVD, with pain, feelings of leg heaviness or tiredness and skin changes. CVD and cardiovascular disease are usually treated by different specialists. A symposium was held at the XIX World Congress of the International Union of Phlebology in Istanbul, Turkey, in September 2022, to raise awareness of the relationship between the two conditions. The speakers described the common disease processes in CVD and cardiovascular disease, and how patients with CVD are at increased risk of cardiovascular disease, and vice versa. They reiterated the importance of thoroughly assessing patients with either cardiovascular disease or CVD to see if both arterial and venous disease were present. When patients have CVD, international treatment guidelines recommend various conservative treatments, including venoactive drugs, to improve symptoms and signs. There is high-quality evidence to support the use of the venoactive drug, micronized purified flavonoid fraction (MPFF), to improve quality of life and relieve a broad range of CVD symptoms/signs. Large-scale observational studies support the effectiveness of MPFF in a real-world population of patients with CVD compared with other venoactive drugs." @default.
• W4387116214 created "2023-09-29" @default.
• W4387116214 creator A5005792761 @default.
• W4387116214 creator A5051512076 @default.
• W4387116214 creator A5058258578 @default.
• W4387116214 creator A5068562796 @default.
• W4387116214 creator A5070442831 @default.
• W4387116214 creator A5089374012 @default.
• W4387116214 date "2023-09-28" @default.
• W4387116214 modified "2023-10-17" @default.
• W4387116214 title "Cardiovascular Insights for the Appropriate Management of Chronic Venous Disease: A Narrative Review of Implications for the Use of Venoactive Drugs" @default.
• W4387116214 cites W1664566016 @default.
• W4387116214 cites W1977843926 @default.
• W4387116214 cites W1993129360 @default.
• W4387116214 cites W2023386726 @default.
• W4387116214 cites W2031379852 @default.
• W4387116214 cites W2047384553 @default.
• W4387116214 cites W2054552132 @default.
• W4387116214 cites W2059843925 @default.
• W4387116214 cites W2064209539 @default.
• W4387116214 cites W2098750815 @default.
• W4387116214 cites W2099404042 @default.
• W4387116214 cites W2102555939 @default.
• W4387116214 cites W2106792599 @default.
• W4387116214 cites W2117172539 @default.
• W4387116214 cites W2125679749 @default.
• W4387116214 cites W2134272331 @default.
• W4387116214 cites W2138938859 @default.
• W4387116214 cites W2149814309 @default.
• W4387116214 cites W2155438535 @default.
• W4387116214 cites W2156247676 @default.
• W4387116214 cites W2186961646 @default.
• W4387116214 cites W2217524220 @default.
• W4387116214 cites W2409246510 @default.
• W4387116214 cites W2766372255 @default.
• W4387116214 cites W2793298901 @default.
• W4387116214 cites W2793832044 @default.
• W4387116214 cites W2797602311 @default.
• W4387116214 cites W2805193281 @default.
• W4387116214 cites W2894751050 @default.
• W4387116214 cites W2935088444 @default.
• W4387116214 cites W2947376194 @default.
• W4387116214 cites W2972377515 @default.
• W4387116214 cites W2987876349 @default.
• W4387116214 cites W2999628417 @default.
• W4387116214 cites W3000448828 @default.
• W4387116214 cites W3007080699 @default.
• W4387116214 cites W3008335862 @default.
• W4387116214 cites W3008962925 @default.
• W4387116214 cites W3036411535 @default.
• W4387116214 cites W3082947438 @default.
• W4387116214 cites W3089078441 @default.
• W4387116214 cites W3180138357 @default.
• W4387116214 cites W3186690877 @default.
• W4387116214 cites W3190424193 @default.
• W4387116214 cites W3205098624 @default.
• W4387116214 cites W4206813711 @default.
• W4387116214 cites W4213237753 @default.
• W4387116214 cites W4225927980 @default.
• W4387116214 cites W4251038385 @default.
• W4387116214 cites W4251900443 @default.
• W4387116214 cites W4283320473 @default.
• W4387116214 cites W4285719527 @default.
• W4387116214 cites W4307231491 @default.
• W4387116214 cites W4360894026 @default.
• W4387116214 cites W573264958 @default.
• W4387116214 cites W6118018 @default.
• W4387116214 doi "https://doi.org/10.1007/s12325-023-02657-0" @default.
• W4387116214 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37768506" @default.
• W4387116214 hasPublicationYear "2023" @default.
• W4387116214 type Work @default.
• W4387116214 citedByCount "0" @default.
• W4387116214 crossrefType "journal-article" @default.
• W4387116214 hasAuthorship W4387116214A5005792761 @default.
• W4387116214 hasAuthorship W4387116214A5051512076 @default.
• W4387116214 hasAuthorship W4387116214A5058258578 @default.
• W4387116214 hasAuthorship W4387116214A5068562796 @default.
• W4387116214 hasAuthorship W4387116214A5070442831 @default.
• W4387116214 hasAuthorship W4387116214A5089374012 @default.
• W4387116214 hasBestOaLocation W43871162141 @default.
• W4387116214 hasConcept C126322002 @default.
• W4387116214 hasConcept C164705383 @default.
• W4387116214 hasConcept C177713679 @default.
• W4387116214 hasConcept C2777466421 @default.
• W4387116214 hasConcept C2778198053 @default.
• W4387116214 hasConcept C2778213512 @default.
• W4387116214 hasConcept C2779134260 @default.
• W4387116214 hasConcept C71924100 @default.
• W4387116214 hasConceptScore W4387116214C126322002 @default.
• W4387116214 hasConceptScore W4387116214C164705383 @default.
• W4387116214 hasConceptScore W4387116214C177713679 @default.
• W4387116214 hasConceptScore W4387116214C2777466421 @default.
• W4387116214 hasConceptScore W4387116214C2778198053 @default.
• W4387116214 hasConceptScore W4387116214C2778213512 @default.
• W4387116214 hasConceptScore W4387116214C2779134260 @default.
• W4387116214 hasConceptScore W4387116214C71924100 @default.
• W4387116214 hasFunder F4320327235 @default.
• W4387116214 hasLocation W43871162141 @default.
• W4387116214 hasLocation W43871162142 @default.
• W4387116214 hasOpenAccess W4387116214 @default.

• next